GlassScriptPhysician profile
Dunnett C Durando
NPI 1275775322
$76,467.38
in general payments reported to CMS, 2019-2025
32 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,521 · 2021: $937 · 2022: $883 · 2023: $13K · 2024: $25K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Food and Beverage: $5,565 · Travel and Lodging: $380 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,920.00 |
| Food and Beverage | $5,564.63 |
| Travel and Lodging | $379.86 |
| Education | $375.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57,468.94 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $12,247.36 | 2019-2025 | |
| Janssen Biotech, INC. | $1,321.65 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $1,068.95 | 2019-2025 | Skyrizi |
| Genzyme Corporation | $774.04 | 2020-2025 | |
| Lilly USA, LLC | $577.65 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $434.50 | 2019-2025 | Blu-U |
| Mayne Pharma Commercial LLC | $321.43 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $279.85 | 2019-2025 | |
| Leo Pharma INC. | $275.69 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $211.89 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $204.45 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $188.86 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $182.41 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $135.32 | 2021-2025 | Aklief, Oracea, Epsolay |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.74 | 2023-2025 | Spevigo |
| Janssen Pharmaceuticals, INC | $100.99 | 2019 | |
| Dermavant Sciences, INC. | $97.05 | 2023-2024 | Vtama |
| Incyte Corporation | $67.97 | 2021-2025 | Opzelura |
| Dermira, INC. | $63.17 | 2019-2020 | |
| Biofrontera INC. | $40.59 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Celgene Corporation | $38.68 | 2019 | |
| Almirall LLC | $37.59 | 2021 | |
| Merz North America, INC. | $34.74 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.33 | 2019 | |
| Clozex Medical INC | $32.13 | 2022 | |
| Kyowa Kirin, INC. | $25.15 | 2025 | |
| Organon LLC | $24.38 | 2025 | |
| Allergan, INC. | $23.10 | 2021 | |
| Verrica Pharmaceuticals INC. | $21.33 | 2023 | Ycanth |
| Dusa Pharmaceuticals, INC. | $20.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dunnett Durando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.